Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Placebo Controlled Double-Blind, Parallel Group, Individualizing Dosing Study Optimizing Treatment of Adults With Attention Deficit Hyperactivity Disorder to an Effective Response With OROS Methylphenidate
Brief Summary: The purpose of this study is to compare the ADHD symptom response of adults with ADHD treated with OROS MPH to those treated with placebo.


Options:
A: Inclusion Criteria:

* Case group:

Case group I: The cases with childhood ADHD diagnosis diagnosed as ADHD after interview Case group II: The cases with sufficient ADHD symptoms for diagnosis as DSM-IV ADHD at childhood but never assessed or treated for ADHD in childhood

* Control group：The subjects without the DSM-IV-TR diagnosis of ADHD or any major psychiatric disorders.

Exclusion Criteria:

* Comorbid with DSM-IV-TR diagnosis of pervasive developmental disorder, schizophrenia, schizoaffective disorder, delusional disorder, other psychotic disorder, organic psychosis, schizotypal personality disorder, bipolar affective disorder, severe anxiety disorder(such as OCD, ASD or PTSD) and mental retardation.
* In the major depressive episode, comorbid with severe anxiety disorders or during substance intoxication or withdrawal at the time of evaluation.
* With neurodegenerative disorder, epilepsy, involuntary movement disorder, congenital metabolic disorder, brain tumor, history of severe head trauma, and history of craniotomy.
* With visual or hearing impairments, or motor disability which may influence the process of neuropsychological assessment.
B: Inclusion Criteria:

* Adults
* ADHD diagnosis (any type: Combined, Predominantly Inattentive, or Predominantly Hyperactive-Impulsive)
* Patients with an Adult ADHD Investigator Symptom Rating Scale (AISRS) score greater than 24 at screening/baseline
* Ability to read and understand English

Exclusion Criteria:

* Any significant history of cardiovascular disease or cardiovascular disease detectable via ECG
* History of diagnosis of substance or alcohol dependence or admission/hospitalization for rehabilitation for dependence
* Current neurologic or psychiatric diagnosis that would make patient inappropriate for participation
* Anxiety assessments of moderate or severe
* Depression assessments of moderate or severe
* History or current suicidal thoughts or attempts
* Known allergies, hypersensitivity, or intolerance to OROS MPH
C: Inclusion Criteria:

1. Completion of the 40-week core study CRIT124D2302 and Week 40 (End of Study) assessments or Patients who meet predefined criteria for treatment failure, were withdrawn from the core study, and have completed core-study week 40 assessments (Premature Discontinuation Visit)

Exclusion Criteria:

1. Patients who, during the core study, developed any psychiatric condition that requires treatment with medication or that may interfere with study participation and /or study assessments.
2. Patients who during the core study developed cardiovascular disorders.
3. Pregnant women.
4. Patients who developed seizures during the core study.
5. Diagnosis of glaucoma, hyperthyroidism, pheochromocytoma.
6. Diagnosis or family history of Tourette's syndrome.
7. Patients who during the core study developed cerebrovascular disorders such as cerebral aneurysm, vascular abnormalities including vasculitis and stroke

Other protocol-defined inclusion/exclusion criteria may apply
D: Inclusion Criteria:

* Clinical diagnosis of ADHD2
* Smoked cigarettes for at least 3 months
* Currently smoking \> 10 cigarettes/day
* Have an interest in quitting
* Negative urine screen for cocaine, methamphetamine, opiates, benzodiazepines, and marijuana

Exclusion Criteria:

* Have a clinical diagnosis for current abuse or dependence for any psychoactive substance other than nicotine, depression, or anxiety; or a life-time clinical diagnosis of psychosis or bipolar disorder
* Allergic to OROS-MPH
* Pregnant or breastfeeding
* Abnormal electrocardiogram (ECG)
* Taking a Monoamine Oxidase (MAO) Inhibitor
* Taking any medication used for treating either ADHD or smoking
* Use of tobacco products other than cigarettes in the past week
* Blood pressure readings greater than 135/85 and/or a heart rate more than 90 beats per minute on three consecutive clinic visits

Answer: B